Search Results for: search.php

The invention presents a new method for pseudonymizing e.g. patient identifiers in which the pseudonymmization service provider is unable to derive the patient identifier from the pseudonym, but rather this ability is assigned to an authorized third party (Ombudsman). This is achieved by asymmetric and symmetric encryption algorithms and key derivation functions in combination with a new algorithm to pseudonymize a patient identifier. The asymmetric and symmetric encryption algorithms used in the pseudonymization software are approved by the technical directive TR-03116 for eCard-Projects of the German Federal Government. The method/software can be used for pseudonymmization of any sensitive data if they are processed by third-party institutions e.g. patient samples for translational research or bank account data.

This humanized monoclonal antibody efficiently neutralizes HSV fully in-dependent of complement or immune effector cell recruitment and completely abrogates viral cell-to-cell spread, a key mechanism by which HSV escapes humoral immune surveillance.

The aim of radiation therapy is to eradicate a tumor without causing significant damage to contiguous normal tissue. For precise field shaping of the radiation beam multileaf collimators (MLC) have been broadly established. The linear servo MLC presented here provides various advantages over conventionally employed MLCs like reduced size and weight, dynamic leaf movements up to 4 m/s, direct fixation of the linear servo rod to the associated leaf and position sensors are implemented in the linear drives.

70-80% of newly diagnosed breast tumors account for hormone receptor positive breast cancer (also known as luminal breast cancer). The histologic grade of luminal breast cancer is often determined by semi-quantitative methods describing morphologic features related to the differentiation states of the tumor specimen. In order to make a clear-cut classification of luminal breast cancer as either “grade 1” (= low risk) or “grade 3” (= high risk) tumors, DKFZ researchers have developed a 3-protein marker set.

This technology was achieved by a cooperation between McGill University and DKFZ. Brain tumours, such as the highly aggressive glioblastoma multiforme (GBM), are currently the leading cause of cancer-related mortality and morbidity in children. Current diagnosis of brain cancers involve MRI, PET and CT scans, angiographies, followed by biopsies performed either during the resection of the tumor or as a separate procedure via a burr hole. A blood-based test would provide a more economical, i.e accessible and less invasive diagnostic tool. The GBM specific biomarker has been patented and is available for licensing i.e. for companion diagnostics.

The here presented technology provides an apparatus for 4Pi STED which allows to generate a three-dimensional light intensity distribution comprising a very steep light intensity gradient between the areas of minimum and maximum light intensity.